A New Course For AMAG: Expanding Feraheme And Moving Beyond Iron
Executive Summary
AMAG is looking to build out its portfolio by in-licensing or acquiring new commercial products that complement its I.V. iron product Feraheme. The company is in negotiations for multiple assets, while at the same time preparing to launch Feraheme into a broader patient population.
You may also be interested in...
Deal Watch: Tax Policy Changes Claiming Victims Already, As Salix/Cosmo Plans Abandoned
Abandoned deals were the order of the week as the Salix/Cosmo breakup followed Novartis’ exit from hepatitis C drug development and a partnership in that space with Enanta. J&J, however, increased its bet on HCV by acquiring Alios, one of several noteworthy buyouts occurring during the week.
AMAG Pursues Expanded Feraheme Strategy Through Lumara Deal
The biotech is acquiring privately held Lumara and its women’s health product Makena in hopes of using the salesforce once it expands the indication for its I.V. iron product Feraheme into that market.
AMAG’s Turnaround Plans Hit A Snag With Feraheme CRL
FDA declined to approve the I.V. iron in a broad patient population and requested another clinical trial to further evaluate safety. The decision gives rival Daiichi more time to penetrate the market with its I.V. iron Injectafer.